1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Vital Signs - Healthcare News - The Analyst's Perspective - June 2014

This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogen's Eloctate, Qiagen's acquisition of Primera Dx, Roche's acquisition of Genia Technologies, Cue's at-home connected lab test, and the Credihealth Teen Clinic.

LIFE SCIENCES
US FDA Approves Biogen’s Hemophilia A Drug Eloctate
Source: Reuters, June 6, 2014

The US Food and Drug Administration (FDA) announced on Friday, June 6, 2014, that it approved Biogen Idec Inc’s
long-lasting hemophilia A drug, Eloctate, adding it to the company’s portfolio of drugs for non-malignant blood
disorders. Eloctate is the first recombinant clotting factor VIII therapy with prolonged circulation in the body,
which eliminates at least one dosing every week for prophylactic use in both children and adults.
The Analyst’s Perspective by Steven Atkinson, Senior Industry Analyst,
Life Sciences, North America

Biogen’s product line continues to grow, especially in the blood disorder area. Eloctate is the second hemophilia
drug approved by the FDA in the past three months, beating the likes of Novo Nordisk and Baxter to market.
Alprolix for hemophilia A was approved in March 2014. These two FDA approvals are the results of Biogen’s
fruitful collaboration with Sobi (Swedish Orphan Biovitrum).

Eloctate was used as a prophylactic in a pediatric study; kids experienced a median annual bleeding rate of 2.0.
Close to half of the subjects had no bleeding episodes to report, and 96% of the children who did experience an
episode said their bleeding was controlled after one or two doses.

Hemophilia A and B combined market population is more than 160, 000 worldwide, with a total combined market
revenue of $7 billion annually. Eloctate and Alprolix are estimated to have combined revenues of over $1.5 billion
by 2019. As an analyst, I would deem this collaboration to be a fairly successful deal if those estimates are met.
With the addition of these recent approvals to Biogen’s current portfolio of multiple sclerosis drugs, Avonex,
Tecfidera and Tysabri, Biogen can possibly tout two blockbuster drugs in the coming years.

Qiagen Buys Primera Dx and Expands its Companion Diagnostics Portfolio
Source: Genomeweb, June 5, 2014
Qiagen, a global giant in the molecular diagnostics segment, recently announced that it acquired PrimeraDx, a
molecular diagnostics start-up in the Boston area. PrimeraDx is primarily known for its flagship product, Modaplex
(also known as the ICEPlex), a multi-analytic and multi-modal testing system. Modaplex is the first of its kind to
use multiple assays for a single sample. It enables the analysis of multiple biomarkers in a single reaction.
The Analyst’s Perspective by Aishwarya Vivekanandan, Industry Analysts,

Life Sciences, North America
Molecular diagnostics is the fastest growing segment in the overall IVD market. The double-digit growth is
primarily contributed by the expanding companion diagnostics market. Large pharmaceutical companies have long
since moved away from the one-size-fits-all model in drug development, realizing the importance of diagnostics
in personalized therapy. Many of these pharmaceutical companies incorporate and partner with global majors
like Qiagen to monitor their developed drugs to encourage personalized medication with patients. This is one of
the underlying reasons that led to the acquisition of PrimeraDx by Qiagen. There were a few other compelling
reasons why Qiagen made the strategic move of acquiring PrimeraDx:

Table Of Contents

Vital Signs - Healthcare News - The Analyst's Perspective - June 2014
LIFE SCIENCES
US FDA Approves Biogen's Hemophilia A Drug Eloctate.. 2
Qiagen Buys Primera Dx and Expands its Companion Diagnostics Portfolio... 2
Roche Acquires Sequencing Technology Startup Genia Technologies
for $350M, Pending Milestones. 3
Cue to Offer at-Home, Smartphone - Connected Lab Tests... 4
Credihealth Teens Clinic: An Online Clinic for Teenagers.. 6

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.